` QTRX (Quanterix Corp) vs S&P 500 Comparison - Alpha Spread

QTRX
vs
S&P 500

Over the past 12 months, QTRX has underperformed S&P 500, delivering a return of -74% compared to the S&P 500's 12% growth.

Stocks Performance
QTRX vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
QTRX vs S&P 500

Loading
QTRX
S&P 500
Difference

Performance By Year
QTRX vs S&P 500

Loading
QTRX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Quanterix Corp vs Peers

S&P 500
QTRX
0KHE
TMO
DHR
207940
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Quanterix Corp
Glance View

Market Cap
173.4m USD
Industry
Life Sciences Tools & Services

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.

QTRX Intrinsic Value
15.6 USD
Undervaluation 71%
Intrinsic Value
Price
Back to Top